Strategic funding Recent venture funding of 18.5M in 2024 indicates strong investor confidence and a runway to advance preclinical and clinical efforts, presenting opportunities to align partnerships or co-development deals with investors and strategic pharma.

Recognition leverage Awards for top drug delivery platform and top company can be used to open conversations with potential partners, lenders, and customers by signaling credibility, innovative delivery capabilities, and market relevance.

Clinical focus Emphasis on intranasal and nontraditional delivery of monoterpenes for cancer treatment suggests a niche of collaboration with oncology-focused CROs, academia, and biotech firms seeking novel delivery mechanisms to improve efficacy or reduce side effects.

Public company IPO status and Nasdaq listing indicate a mature corporate structure and potential access to capital markets; explore strategic licensing, co-development, or royalty-based partnerships with larger biopharma aiming to augment portfolio diversification.

Low revenue footprint Current revenue under 1M highlights an early-stage profile; ideal sales approach centers on non-dilutive grants, research collaborations, and milestone-driven partnerships with larger biotechs to de-risk initial engagements.